Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy

The use of immune checkpoint inhibitors (ICIs) in combination with thoracic radiotherapy (TRT) has gained significant traction in treating advanced cancers [1]. However, both ICIs and TRT are independent causative factors for pneumonitis, which can lead to unexpectedly high incidences of radiation pneumonitis (RP) with combinatorial therapy [2,3]. To this extent, our previous study (of patients receiving ICIs prior to TRT) revealed a 40% rate of symptomatic grade ≥2 RP, including two fatalities [4].

Source: Radiotherapy and Oncology - December 7, 2023 Category: Radiology Authors: Tingting Nie, Zien Chen, Jun Cai, Shuangquan Ai, Xudong Xue, Mengting Yuan, Chao Li, Liting Shi, Yulin Liu, Vivek Verma, Jianping Bi, Guang Han, Zilong Yuan Source Type: research